| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169780 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(8 days from now) | |
| US7754731 | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7217713 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(11 months ago) | |
| US7435734 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(11 months ago) | |
|
US7435734 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(5 months ago) | |
|
US7217713 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(5 months ago) | |
|
US7169780 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(6 months from now) | |
|
US7754731 (Pediatric) | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(5 years from now) | |
| US9649311 | MERCK SHARP DOHME | Solid pharmaceutical compositions containing an integrase inhibitor |
Oct, 2030
(7 years from now) | |
|
US9649311 (Pediatric) | MERCK SHARP DOHME | Solid pharmaceutical compositions containing an integrase inhibitor |
Apr, 2031
(7 years from now) | |
| US10772888 | MERCK SHARP DOHME | Solid pharmaceutical compositions containing an integrase inhibitor |
Mar, 2032
(8 years from now) | |
Isentress is owned by Merck Sharp Dohme.
Isentress contains Raltegravir Potassium.
Isentress has a total of 11 drug patents out of which 4 drug patents have expired.
Expired drug patents of Isentress are:
- US7217713
- US7435734
- US7435734*PED
- US7217713*PED
Isentress was authorised for market use on 12 October, 2007.
Isentress is available in tablet;oral dosage forms.
Isentress can be used as treatment of hiv-1 infection, treatment of hiv infection, treatment of hiv infection; integrase inhibition for the treatment of hiv infection.
The generics of Isentress are possible to be released after 30 March, 2032.
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 12 October, 2007
Treatment: Treatment of hiv infection; Integrase inhibition for the treatment of hiv infection; Treatment of hiv-1 infection
Dosage: TABLET;ORAL
ISENTRESS family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8852632 | MSD SUB MERCK | Pharmaceutical formulation containing a release rate controlling composition |
Jan, 2028
(4 years from now) | |
| US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(6 years from now) | |
Isentress is owned by Msd Sub Merck.
Isentress contains Raltegravir Potassium.
Isentress has a total of 2 drug patents out of which 0 drug patents have expired.
Isentress was authorised for market use on 12 October, 2007.
Isentress is available in tablet;oral dosage forms.
Isentress can be used as treatment of hiv infection.
The generics of Isentress are possible to be released after 02 June, 2030.
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 12 October, 2007
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
ISENTRESS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic